ecancermedicalscience

Review

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

22 Oct 2015
Nicoletta Tomasi Cont, Annamaria Ferrero, Fedro Peccatori, Marta D'Alonzo, Giovanni Codacci-Pisanelli, Nicoletta Colombo, Nicoletta Biglia

Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge.

For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain.

Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient’s performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients’ quality of life.

Related Articles

Ranti Ghosh, Debarshi Lahiri, Debjit Ghosh, Kushal Sen, Debanjan Chakraborty, Tapas Maji, Suparna Mazumder, Ranajit Mandal, Arit Bhattacharjee, Jayanta Chakrabarti
Chinelo C Nduka, Chizobam A Nweke, Runcie C W Chidebe, Candidus Nwakasi
Mariana Carvalho Gouveia, Renata Colombo Bonadio, Felippe Lazar Neto, Maísa Maria Spagnol Trento, Mateus Trinconi Cunha, Mariana Scaranti